Can obstructive sleep apnea fragment deep sleep and impair glymphatic clearance?

OSA is a credible contributor to disrupted sleep physiology that may affect brain waste-transport pathways relevant to Alzheimer disease. The overall evidence supports the claim, with the strongest direct data for OSA-related sleep fragmentation and preclinical glymphatic mechanisms; human evidence for clearance remains largely proxy-based.

Sleep and glymphatic effects

• OSA reliably causes recurrent respiratory arousals, stage transitions, and reduced sleep continuity. N3/slow-wave sleep may be delayed or reduced, especially with more severe OSA, although total N3 loss is not uniform across patients.
• Human MRI studies report lower DTI-ALPS—a surrogate of glymphatic function—in OSA, related to apnea and desaturation severity. A meta-analysis of four studies found substantially lower ALPS in severe OSA versus controls (standardized mean difference −0.95, 95% CI −1.46 to −0.44).
• In mice, chronic intermittent hypoxia disrupts perivascular aquaporin-4 (AQP4) polarization and progressively reduces glymphatic influx and efflux. Sleep fragmentation also reduces CSF influx, lymphatic efflux, slow vasomotion, and cortical amyloid-β clearance.

Relevance to amyloid and tau

• Slow-wave/NREM sleep enhances CSF–interstitial-fluid transport. In a randomized human crossover study, normal sleep produced greater overnight brain-to-blood amyloid-β and tau export signals than sleep deprivation.
• Longitudinal human data associate lower ALPS with lower CSF Aβ42, greater amyloid-PET burden, faster amyloid accumulation, and later cognitive decline.
• In tauopathy models, AQP4 loss or inhibition slows extracellular tau clearance and increases phosphorylated/insoluble tau deposition, propagation, neurodegeneration, atrophy, and cognitive impairment.

Bottom line

• For an 83-year-old man, untreated or undertreated OSA is relevant not only to sleep quality but plausibly to amyloid/tau handling through hypoxemia-, arousal-, and AQP4-related disruption of glymphatic transport. This is biologically and clinically credible, but it does not establish that OSA causes Alzheimer disease or that treating OSA has proven effects on amyloid or tau burden.